Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars

• Morphic Therapeutic (NASDAQ: MORF) reported topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with moderate to severe ulcerative colitis (UC).

• Patients receiving MORF-057 experienced a statistically significant reduction in the RHI score and a 25.7% clinical remission rate.

• In addition, MORF-057 was generally well tolerated, with no safety signal observed.

• The most common adverse events were exacerbation of UC and anemia.

• MORF-057 achieved the primary endpoint, demonstrating a statistically significant reduction in the Robarts Histopathology Index (RHI) score of 6.4 points (p=0.002) from baseline to week 12.

• RHI measures histological disease activity in ulcerative colitis.

• In the prespecified secondary endpoint, change in modified Mayo Composite Score, patients had a 2.3-point reduction from baseline.

• The company's EMERALD-2 Phase 2b trial of MORF-057 enrolling patients with moderate-to-severe UC.

• The primary endpoint of EMERALD-2 is the clinical remission rate as measured by mMCS at 12 weeks and is expected to report in the first half of 2025.

• Morphic says its cash, cash equivalents, and marketable securities of $421 million will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2026.

• Price Action: MORF shares are up 23.10% at $53.52 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.